Harpoon Therapeutics

Merck advances lung cancer attack, pocketing $170M from Daiichi and plotting ADC-trispecific combo
Fierce Biotech
Tue, 08/6/24 - 11:20 am
Merck
Harpoon Therapeutics
Daiichi Sankyo
small cell lung cancer
Biopharma M&A more than doubled in the first quarter compared to the year prior: report
Fierce Biotech
Thu, 04/18/24 - 11:11 am
M&A
biotech
AstraZeneca
Merck
Gracell
Harpoon Therapeutics
Merck inks $680M Harpoon buyout, spearing challenger to Amgen T-cell engager
Fierce Biotech
Mon, 01/8/24 - 11:36 am
Merck
Harpoon Therapeutics
M&A
T-cell engager
JPMHC 2024
AbbVie Passes on License Option for Harpoon’s TriTAC Multiple Myeloma Program
BioSpace
Thu, 09/14/23 - 10:02 am
AbbVie
Harpoon Therapeutics
HPN217
Multiple Myeloma
Biotechs reveal layoffs, research revamps in third quarter earnings
BioPharma Dive
Wed, 11/16/22 - 11:13 pm
layoffs
Tricida
Freeline Therapeutics
Harpoon Therapeutics
Adamis Pharmaceuticals
Neoleukin
NexImmune
Band of biotechs cut pipeline prospects to focus cash on priority programs
Fierce Biotech
Thu, 08/11/22 - 11:30 pm
ProQR Therapeutics
Harpoon Therapeutics
Kala Pharmaceuticals
Synthetic Biologics
ASCO 2022 – the spirit of Rova-T struggles to live on
EP Vantage
Tue, 06/7/22 - 10:19 am
ASCO 2022
Rova-T
AbbVie
Harpoon Therapeutics
Amgen
Boehringer Ingelheim
Harpoon cuts bait with lead program after failing to find silver linings from ASCO data, other studies
Endpoints
Fri, 03/11/22 - 11:04 am
Harpoon Therapeutics
HPN424
prostate cancer
ASCO 2021 movers – PDS wins, but big pharma reigns
EP Vantage
Wed, 06/9/21 - 11:00 am
ASCO 2021
PDS Biotechnology
Spectrum Pharma
Black Diamond Therapeutics
Alpine Immune Sciences
Harpoon Therapeutics
Macrogenics
AbbVie signs potential $2.4bn cancer immunotherapy deal with Harpoon
Pharmaforum
Thu, 11/21/19 - 10:39 am
AbbVie
Harpoon Therapeutics
R&D
BCMA
Multiple Myeloma
BioSpace's List of February 2019 Life Science IPOs
BioSpace
Mon, 02/11/19 - 08:22 pm
IPOs
Shockwave Medical
Harpoon Therapeutics
Gossamer Bio
Alector
Hoth Therapeutics
Harpoon lands $75.6M in NASDAQ IPO
BioCentury
Thu, 02/7/19 - 11:26 pm
Harpoon Therapeutics
IPOs
Another Immuno-Oncology Company, Another $90+ Million IPO
CP Wire
Mon, 02/4/19 - 10:59 pm
Harpoon Therapeutics
IPOs
immuno-oncology
Another Immuno-Oncology Company, Another $90+ Million IPO
Mon, 02/4/19 - 10:56 pm
Harpoon Therapeutics
IPOs
immuno-oncology
At the Eleventh Hour, Harpoon Therapeutics Signs up to Join the 2018 IPO Game
BioSpace
Fri, 12/28/18 - 01:11 pm
Harpoon Therapeutics
IPOs
tech
Harpoon Therapeutics Banks $70M Series C Financing
CP Wire
Mon, 11/12/18 - 09:17 am
Harpoon Therapeutics
Harpoon Therapeutics Banks $70M Series C Financing
Sun, 11/11/18 - 09:33 pm
Harpoon Therapeutics
Harpoon Therapeutics Begins Trial of Novel Immuno-Oncololgy Drug in Patients with Metastatic Castration-Resistant Prostate Cancer
CP Wire
Mon, 08/6/18 - 09:46 am
Harpoon Therapeutics
HPN424
metastatic castration-resistant prostate cancer
Harpoon Therapeutics Begins Trial of Novel Immuno-Oncololgy Drug in Patients with Metastatic Castration-Resistant Prostate Cancer
Mon, 08/6/18 - 09:20 am
Harpoon Therapeutics
HPN424
metastatic castration-resistant prostate cancer